Skip to main content
Equibles
ALNY logo

ALNY · Alnylam Pharmaceuticals, Inc. · Held by Funds

Track ALNY — free

Use ALNY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ALNY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$246.74 -7.33 (-2.89%) At close · Sep 30
Nasdaq-100 member Russell 1000 member Rebalance outlook locked
Market Cap
$34.17B
Shares
133.81M
Volume · Sep 30 1.04M Avg daily vol (3M) 1.8M

Registered funds — mutual funds, ETFs and closed-end funds — whose latest Form N-PORT portfolio report holds this exact listed security, matched by CUSIP. Each row is one fund position with its size, value and weight in that fund.

Funds holding ALNY

747 fund positions
Fund Balance Value % of Fund Open
Growth Fund of America 7,670,994 $2,316,486,768 0.64%
VANGUARD TOTAL STOCK MARKET INDEX FUND 4,239,087 $1,276,092,360 0.06%
AMCAP Fund 4,101,680 $1,238,625,326 1.27%
VANGUARD MID-CAP INDEX FUND 2,893,030 $870,888,821 0.39%
Invesco QQQ Trust, Series 1 2,834,095 $853,147,618 0.17%
T. Rowe Price Capital Appreciation Fund 2,034,761 $612,524,104 0.87%
VANGUARD GROWTH INDEX FUND 1,624,001 $488,873,021 0.13%
Investment Co of America 1,612,942 $485,543,930 0.26%
VANGUARD EXTENDED MARKET INDEX FUND 1,530,865 $460,836,291 0.47%
Fidelity OTC Portfolio 2,140,824 $439,982,148 1.02%
VANGUARD HEALTH CARE FUND 2,136,580 $439,109,922 1.15%
Fidelity Growth Company Fund 1,338,874 $404,313,171 0.41%
Dodge & Cox Stock Fund 1,233,200 $371,230,196 0.31%
Growth Fund 1,197,876 $360,596,612 0.63%
T. Rowe Price Mid-Cap Growth Fund, Inc. 1,165,773 $350,932,646 1.52%
VANGUARD MID-CAP GROWTH INDEX FUND 1,022,888 $307,919,975 0.88%
New Perspective Fund 1,020,320 $307,146,930 0.18%
Strategic Advisers Fidelity U.S. Total Stock Fund 955,780 $288,626,444 0.12%
iShares Biotechnology ETF 942,174 $283,622,639 3.12%
American Balanced Fund 800,000 $240,824,000 0.08%
iShares Russell Mid-Cap Growth ETF 786,679 $236,813,979 1.10%
New Economy Fund 723,459 $218,470,149 0.42%
Fidelity Extended Market Index Fund 684,324 $206,652,162 0.48%
Fidelity Advisor Growth Opportunities Fund 635,135 $191,798,067 0.54%
Capital Group Growth ETF 613,330 $185,213,393 0.76%
JPMorgan Mid Cap Growth Fund 605,988 $182,420,568 1.38%
American Funds Fundamental Investors 600,000 $180,618,000 0.10%
Invesco NASDAQ 100 ETF 563,667 $170,216,161 0.18%
VANGUARD U.S. GROWTH FUND 554,294 $167,385,702 0.35%
iShares Russell Mid-Cap ETF 548,234 $165,034,881 0.29%
Select Biotechnology Portfolio 511,683 $154,518,032 2.93%
iShares Russell 1000 Growth ETF 509,032 $153,233,903 0.12%
JNL/T. Rowe Price Capital Appreciation Fund 478,850 $144,148,216 0.94%
Ultra Fund 688,000 $141,397,760 0.55%
Select Health Care Portfolio 460,000 $138,910,800 2.40%
Asset Allocation Fund 460,972 $138,766,401 0.49%
JPMorgan Growth Advantage Fund 409,574 $123,294,061 0.55%
VANGUARD HEALTH CARE INDEX FUND 396,853 $119,841,669 0.63%
Fidelity Growth Company K6 Fund 367,813 $111,072,170 0.40%
iShares MSCI USA Min Vol Factor ETF 519,903 $106,850,465 0.45%
Fidelity Advisor New Insights Fund 350,780 $105,595,303 0.37%
Fidelity Mid Cap Index Fund 505,045 $103,796,848 0.20%
State Street(R) SPDR(R) S&P(R) Biotech ETF 341,887 $102,918,244 0.96%
Growth-Income Fund 341,194 $102,709,630 0.22%
Fidelity Contrafund 315,780 $95,059,253 0.05%
Heritage Fund 450,954 $92,680,066 1.74%
Fidelity Series Growth Company Fund 303,631 $91,690,489 0.37%
Fidelity Blue Chip Growth Fund 442,665 $90,976,511 0.09%
MFS Mid Cap Growth Fund 285,915 $86,340,612 0.63%
Schwab U.S. Large-Cap Growth ETF 282,385 $85,274,622 0.14%
Showing 1–50 of 747 positions
Key facts CIK 1178670 CUSIP 02043Q107 13F (30d) 20 filings 16 filers Visit website Investor relations